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Abstract
Objective: The aim of this study is to evaluate the safety of outpatient
anticoagulation bridging following left ventricular assist device (LVAD)
implantation.
Methods: This study is a retrospective, single-center cohort of adult patients who
underwent LVAD implantation (HeartMate II™ or HeartMate 3™) and received
warfarin and at least one dose of therapeutic enoxaparin or fondaparinux for
outpatient anticoagulation bridging. The primary endpoint was the incidence of
bleeding complications within one week of completing the bridging episode.
Secondary endpoints included the incidence of new hemolysis or thrombosis
within 30 days, INR at the time of bridge initiation, duration of anticoagulation
bridge, and management of bleeding events associated with the bridging episode.
Results: Data from 155 bridging episodes in 44 patients were analyzed. The
primary endpoint occurred 30 times during 26 encounters. Of these events, 14
systemic bleeding episodes (9.03%) occurred. Localized bleeding complications
consisted of injection site adverse reactions, including bruising (7.74%), bleeding
(1.94%), and hematomas (0.65%). The majority of bleeding episodes were
successfully self-managed by the patient and required monitoring only (83.33%).
Only one new hemolysis event occurred (0.65%) and no new thrombotic events
occurred within 30 days of any bridging episode.
Conclusion: Results of this study suggest that pharmacist-managed outpatient
anticoagulation bridging may be safely initiated in the LVAD patient population,
given patients have close follow-up monitoring.
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Introduction
The left ventricular assist device (LVAD) is a mechanical circulatory support pump
that augments systemic blood flow by assisting the left ventricle in ejecting blood
to the aorta.1 These devices are generally reserved for patients with end-stage
heart failure who are refractory to standard medical therapies. Both the HeartMate
II™ and HeartMate 3™ LVADs (Abbott) are FDA-approved to provide
intermediate-to-chronic hemodynamic support to both patients awaiting heart
transplant (i.e., bridge to transplant) and patients who are ineligible for transplant
(i.e., destination therapy).1
Although LVAD implantation has been associated with prolonged survival and
improved quality of life, these devices carry an intrinsic risk of bleeding, and
thromboembolic (e.g. pump thrombosis, stroke) complications.2 To reduce the risk
of thrombotic complications, systemic anticoagulation is recommended postimplantation.3 Current standards of care post-LVAD implantation include an
antiplatelet agent (aspirin, generally) and warfarin titrated to an international
normalized ratio (INR) of 2.0-3.0.4,5 Although associated with a decreased
incidence of thrombotic events, anticoagulation therapy further enhances the
bleeding potential. Therefore, careful monitoring and management of anticoagulant
therapy is required to mitigate the competing risks of bleeding and thrombosis.
Previous studies have demonstrated that LVAD patients whose warfarin therapy is
managed by pharmacists have higher time in therapeutic range versus usual care,
without significant difference in bleeding or thrombosis.6,7
Despite appropriate dosing and monitoring, there is a potential for significant
variations in anticoagulation status in patients receiving warfarin. Minimal data
exist regarding the safety and efficacy of outpatient anticoagulation bridging with
rapid-acting parenteral anticoagulants (e.g. enoxaparin, fondaparinux) in this
patient population. Limited data suggest that there may be up to a four-fold
increase in major bleeding events during the low molecular weight heparin
(LMWH) bridging period.8 Trials assessing the need for periprocedural bridging in
patients with non-valvular atrial fibrillation have shown that the risk of bleeding
often outweighs the potential benefit, since the short-term risk of thrombotic
complications (i.e. stroke) is less than one percent, however this study was not
conducted on LVAD patients.9 The objective of this study was to evaluate the
safety of outpatient anticoagulation bridging with treatment-dose enoxaparin or
fondaparinux in patients who have undergone LVAD implantation.

Methods
Study Design, Setting, and Patient Population
This study was a single-center retrospective cohort study. Patients included were
adults 18 years of age and older who had undergone implantation of either
HeartMate II or HeartMate 3 LVAD at our institution. All subjects were outpatients
receiving concurrent warfarin therapy and at least one dose of enoxaparin or
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fondaparinux as a bridge to therapeutic INR between September 1, 2015 and June
30, 2018. Warfarin and bridging therapy was managed by clinical pharmacists
using an established protocol, operating under collaborative practice agreements
within the Advanced Heart Failure (AHF) service. The protocol allows pharmacists
to independently initiate bridging when the INR is less than 1.8 For most patients,
dosing for enoxaparin is 1 mg/kg every 12 hours, rounded to the nearest 10 mg or
nearest syringe size, with a typical maximum dose of 120 mg. Dosing for
fondaparinux is 5 mg daily for patients weighing less than 50 kg, 7.5 mg daily for
patients weighing 50 to 100 kg, and 10 mg daily for patients weighing more than
100 kg. Both enoxaparin and fondaparinux are dosed based on the patient's total
body weight. For complex patient cases (e.g. borderline therapeutic INR,
creatinine clearance (CrCl) <30 mL/min, prior major bleeding event, or actual body
weight greater than 120 kg) the pharmacist and AHF clinic attending physician
collaborate to determine the optimal anticoagulation regimen.
Criteria for study exclusion included transfer of care outside our health system, any
hospitalization before completion of outpatient bridging episode, patient reported
non-adherence to the prescribed anticoagulation regimen, and incomplete medical
record documentation. The decision to exclude patients who were hospitalized
before completion of an outpatient bridging episode was based on the potential for
the hospitalization to act as a confounding variable. Upon hospitalization, bridging
may be discontinued for a variety of reasons and if continued, would be
administered by a healthcare professional, rather than self-administered by the
patient. Additionally, anticoagulation therapy is often held or adjusted during
hospitalizations due to the need for invasive procedures. Pregnant women and
prisoners were also excluded from this analysis. The study protocol was approved
by the local institutional review board.

Data Collection
Clinical data was collected retrospectively through review of the electronic medical
record, including progress notes documented by both clinical pharmacists and
physicians. Data collection included demographic information, pre-specified
laboratory results, pertinent concomitant medications, number and dose of
enoxaparin or fondaparinux injections, and adverse outcomes (e.g. bleeding
events, hemolysis/thrombotic events).

Endpoints
The primary endpoint was the incidence of patient-reported or provider-diagnosed
(via complete blood count results) localized or systemic bleeding complications
within 7 days of completing an anticoagulation bridging episode. Secondary
endpoints included the incidence of new hemolysis or thrombotic events within 30
days. Additional variables collected for primary endpoint analysis included the time
from device implantation to first bridging episode in patients who underwent device
implantation between August 1, 2015 and June 30, 2018, pre- and post-bridge
lactate dehydrogenase (LDH), INR at the time of bridge initiation, etiology of
subtherapeutic INRs, duration of bridging episodes, management of bleeding
events, post-bridge platelet count, time to localized bleeding, and time to systemic
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bleeding. Hemolysis was defined as elevated LDH greater than or equal to 600
IU/L (2.5 times the upper limit of normal), in accordance with current practice
guidelines.3,10

Analysis
The results were downloaded and reviewed. Questions with “yes,” “no,” and
“sometimes” answer choices were assigned values of 1 (yes), 0 (no), and 0.5
(sometimes). Answers from programs with multiple respondents were consolidated
to a single response. Questions of fact were assigned the majority response, while
questions of perspective were averaged based on the assigned value of each
answer. Average answers of >0.5 were considered “yes,” and average answers of
<0.5 were considered “no” for questions without a sometimes option. Questions
involving ranking were consolidated by averaging the rank of each response and
re-ordering based on the averages. If the average answer for a question was
indeterminate, the program was excluded for the question.

Results
Characteristics of the Study Population
A total of 54 patients were screened for enrollment, of which 44 qualified for study
inclusion. Ten patients were excluded from the study as a result of not having any
bridging episodes during the study time frame (n=9) or having their care
transferred to another health care system (n=1). Additionally, fifteen bridging
episodes in 12 patients were excluded due to patient hospitalization before
completion of the bridging episode or lack of follow-up. No patients were
hospitalized due to bleeding prior to completion of the bridging episode. In total,
155 bridging episodes were included in the analysis.
Recent dietary modification was the single most common factor that contributed to
the need for bridging and was reported in 24 encounters (15.48%). Other common
etiologies of subtherapeutic INRs included missed or incorrect warfarin doses
(12.90%), recent warfarin dose changes (9.68%), and clinically significant drug
interaction(s) (6.45%). Twenty-one bridging episodes (13.55%) resulted from a
combination of more than one contributing factor. Investigators were unable to
definitively identify the cause of subtherapeutic INRs in more than one-third of all
encounters (36.77%).
The mean age across encounters was 55 years (Table 1). The majority of included
patients were male (n=36). The HeartMate II LVAD was the primary device
implanted in most patients (93.18%). At the time of their bridging event, 43.18% of
patients had a history of LVAD-related hemolysis or thrombosis and 18.18% of
patients had a history of LVAD-related bleeding. Enoxaparin was the predominant
bridging anticoagulant and was prescribed in all but two encounters (98.71%). The
mean enoxaparin dose used was 0.95 mg/kg actual body weight, and almost all
patients were prescribed enoxaparin at a frequency of every 12 hours (96.08%).
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Bridging was initiated at a mean INR of 1.62, and episodes lasted an average of
4.7 days. Concomitant octreotide therapy was prescribed in 2 patients (4.55%) in
the study.

Table 1. Patient Demographics
n = 44 patients
Age (yr) – mean age across bridging encounters (SD)

55.07 (± 11.52)

Male gender – no. (%)

36 (81.82%)

Race – no. (%)
White
Black
Other

25 (56.82%)
17 (38.64%)
2 (4.54%)

Weight (kg) – mean (SD)

96.13 (± 17.37)

Creatinine clearance (mL/min) – mean (SD)

83.12 (± 28.39)

Baseline platelet count (109/L)– mean (SD)

231.38 (± 61.87)

Type of LVAD – no. (%)
HeartMate II™
HeartMate 3™

41 (93.18%)
3 (6.82%)

History of LVAD-related bleeding at the time of the
bridge – no. (%)

8 (18.18%)

History of LVAD-related hemolysis/ thrombosis at
time of bridge – no. (%)

19 (43.18%)

Bridging anticoagulant used – no. (%)
Enoxaparin
Fondaparinux

43 (97.73%)
1 (2.27%)

Antiplatelet therapy – no. (%)†
Aspirin 81 mg
Aspirin 325 mg
None

39 (88.64%)
1 (2.27%)
4 (9.09%)

†Five patients switched antiplatelet regimens during the
study time frame
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Study Outcomes
Primary and secondary outcomes are described in Table 2 and Table 3. Localized
bleeding complications occurred within 7 days of bridge discontinuation in 16
encounters in 13 patients (10.32%). The majority of these events were attributed to
either bruising or bleeding at the injection site (n=15; 93.75%). Systemic bleeding
complications were reported in 14 encounters in 8 patients (9.03%). Of these,
epistaxis (n=6), hematuria (n=2), and gastrointestinal bleeding (n=2) were the
most frequently reported adverse reactions. The majority of bleeding events were
self-managed (83.3%), though 5 encounters (16.67%) required provider follow up.
Provider management of the bleeding events were as follows: no change in
therapy (n=2), held one dose of warfarin (n=1), enoxaparin discontinued (n=1),
CBC ordered and enoxaparin continued (n=1). No bleeding events resulted in a
hospitalization or required a blood transfusion, and all were effectively managed in
the outpatient setting. One patient (2.27%) developed new hemolysis within 30
days of a bridging episode, despite adherence to anticoagulation as advised. Of
the 155 bridging encounters, 7.09% were associated with a subtherapeutic INR
less than 2.0 at the time of bridge discontinuation, versus 16.77% with a
supratherapeutic INR greater than 3 at bridge discontinuation. Only three bridging
episodes (1.9%) were discontinued when the INR was less than 1.8.
Table 2. Primary Outcomes
n = 155
Encounters
Localized bleeding within 1 week of completing bridging
episode
Injection site bruising
Injection site bleeding
Injection site hematoma

16 (10.32%)
12 (7.74%)
3 (1.94%)
1 (0.65%)

Systemic bleeding within 1 week of completing bridging
episode
Bright red blood per rectum
Gingival bleeding
Post-operative bleeding
Epistaxis
Hematuria
Menorrhagia

14 (9.03%)
2 (1.29%)
1 (0.65%)
2 (1.29%)
6 (3.87%)
2 (1.29%)
1 (0.65%)

Overall bleeding was not associated with any of the following variables: creatinine
clearance (p=0.87), pre-bridge INR (p=0.78), post-bridge INR (p=0.38), enoxaparin
dose (p=0.59), or pre- versus post-bridge LDH (p=0.99) according to the Wilcoxon
rank test. Patients who experienced any bleeding event tended to have a lower
mean post-bridge INR compared to those who did not develop bleeding
complications (INR 2.50 versus 2.61, respectively); however, this was not
statistically significant. The mean age of patients who had any bleeding event was
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higher compared to patients who did not experience bleeding events (58.96 ± 8.23
versus 48.44 ± 13.44; p=0.0075).
Table 3. Secondary Outcomes
n = 155
Encounters
New hemolysis within 30 days

1 (0.65%)

New thrombosis within 30 days

0 (0.00%)

Management of bleeding events
Provider follow-up
No change in therapy
One dose of warfarin held
Enoxaparin discontinued
CBC ordered and enoxaparin continued
Self-managed/observation only

30
5 (16.67%)
2
1
1
1
25 (83.33%)

INR at bridge – mean (SD)

1.63 (± 0.19)

INR after bridge – mean (SD)

2.58 (± 0.48)

Post-bridge platelet count (109/L) – mean (SD)

218.76 (±
55.25)

Duration of anticoagulant bridging (days) – mean (SD)

4.69 (± 2.39)

Time to localized bleeding event (days) - mean (SD)

5.58 (± 2.77)

Time to systemic bleeding event (days) – mean (SD)

3.47 (± 2.96)

Discussion
The results of our study appear to be similar to previous trials and suggest
a potential antithrombotic benefit of bridging with enoxaparin in the outpatient
setting for patients with LVADs who have subtherapeutic INRs while on warfarin.
These results suggest that outpatient bridging was associated with a moderate risk
of overall patient-reported bleeding events. However, the majority of bleeding
events were injection-site reactions commonly associated with subcutaneous
medication administration.
More than 80% of systemic bleeding events observed in this study were nuisance
bleeding events, primarily epistaxis, which self-resolved without provider follow-up.
Only one patient with a prior history of bleeding experienced a systemic bleeding
event during a bridging episode, which could suggest that history of bleeding is not
correlated with bleeding during a bridging episode. The overall incidence of
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bleeding in this study was more closely correlated with increasing patient age
rather than impaired renal function, which is likely attributed to appropriate renal
dose adjustments by the clinical team. However, our study included a limited
number of patients with advanced renal disease requiring clinically significant
enoxaparin or fondaparinux dose adjustments.
No substantial risk of hemolysis or thrombosis was identified within 30 days of a
bridging episode, and the single episode of hemolysis did not result in a
subsequent thrombotic event or admission. Although patients in this study did
experience hemolysis and/or thrombotic events during the study timeframe, the
occurrence of these events did not coincide with bridging episodes. This
observation further supports the hypothesis that LMWH is effective when used for
outpatient anticoagulation bridging in the setting of subtherapeutic INRs.
Additionally, given the risk of thromboembolic complications associated with the
HeartMate II device, it is expected that outpatient bridging practices would be
associated with a lower cost of care by avoiding hospitalizations for inpatient
bridging
It is well-established that LVAD patients are at an increased risk of postimplantation complications, including thromboembolism and bleeding.11 The
occurrence of these adverse events complicates anticoagulation management
given their associated healthcare costs and the impact on patient morbidity and
mortality. Prior to initiating and prescribing anticoagulant therapy in the LVAD
population, patient-specific factors related to anticoagulation, such as renal
function, concomitant medications, past INR trends, risk of thrombosis versus
bleeding complications, and patient compliance should be considered. This allows
for individualized treatment modifications, which aim to reduce the risks of
thrombotic or bleeding complications.
The cost of pump replacement in cases of thrombosis is often deemed the most
expensive complication associated with LVADs. A review of data from 2009-2010
determined that the mean cost of initial pump implantation for Medicare
beneficiaries was $175,420, while the cost of pump replacement was $90,147.12
Anticoagulation therapy is used to reduce the risk of thrombotic complications but
is associated with an increased risk of bleeding.3
A previous trial by Bhatia et al. estimated an event rate of 0.53 major bleeding
events per patient-year in patients bridged with enoxaparin for subtherapeutic INR,
making bleeding complications the most common complication associated with
anticoagulation in patients with LVADs.8 The high bleeding rates observed in that
trial as compared to our study could possibly be due to the long mean duration of
bridge (18 days), as well as the inclusion of in-patient periprocedural and posthospitalization bridging, which were excluded in our study.
Strengths of this study include the diversity of the patient population in terms of
gender, race, and baseline history of LVAD related complications, robust
documentation of anticoagulation management outcomes, and a relatively large
sample of bridging encounters. Patients included in this study had close follow-up
monitoring by clinical pharmacists during each bridging episode, with INRs being
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evaluated at least twice weekly during periods of sub- or supratherapeutic
anticoagulation.

Limitations
Limitations of this study include its retrospective, single-center study design,
relatively small patient sample size, and minimal inclusion of fondaparinux and
HeartMate 3 devices. Additionally, the descriptive study design of this assessment
limits our ability to assess the comparative risk of bleeding and thrombosis in
patients who did not receive anticoagulation bridging in response to subtherapeutic
INRs. Given that the HeartMate 3 device has a lower intrinsic risk of
thromboembolic complications compared to other durable LVADs, the risk of
bleeding associated with anticoagulation bridging may outweigh the slight risk of
thrombosis.5 Because adverse events and compliance were self-reported by
patients, investigators may not have been able to fully capture all outcomes.
Additionally, the impact of unmeasured confounding factors (e.g. procedures) may
have influenced outcomes. Future studies are warranted to further define optimal
anticoagulation practices in this population, including the INR threshold for
initiating bridging and the duration of bridging episodes, as well as to determine
the most effective strategies for preventing and managing complications.
Surveys of this nature have several limitations that impact the ability to include a
totality of responses. Selection bias was likely present as known SWs were
contacted to complete the survey, in addition to posting on the sites described
above. Additionally, our limited sample size may or may not accurately reflect the
larger consensus of the field. With respect to the team member survey, it must be
considered that respondents may not have a full understanding of the role that the
VAD SW fills at their program. As a result, answers may not encompass the entire
scope of the SWs activity in some cases. In addition, physicians were
underrepresented among VAD team member respondents. As the leaders of the
VAD care team, it is perhaps most important to understand the physician
perspectives of the VAD SW.

Conclusion
The results of this study demonstrate that outpatient anticoagulation
bridging with enoxaparin in patients with LVADs was associated with a moderate
risk of localized minor bleeding complications at the injection site. The overall
incidence of bleeding seen was about 20%, however the incidence of systemic
bleeding requiring provider follow-up seen in this study was minimal, with nearly
half of all systemic bleeding consisting of epistaxis. New hemolysis and thrombotic
events were generally not associated with bridging episodes. Overall, these results
suggest that enoxaparin may be considered in the outpatient setting as a shortterm bridge in LVAD patients with subtherapeutic INRs. Given the incidence of
bleeding observed in this study, it is important that clinicians weigh the risk of
bleeding versus thrombotic events on a case-by-case basis when considering
enoxaparin as a bridging strategy. If a bridging strategy is implemented, close

The VAD Journal: Outpatient Anticoagulation Bridging after LVAD

Page 9 of 11

The VAD Journal: The journal of mechanical assisted circulation and heart failure

patient follow-up may help minimize the risk of bleeding by ensuring prompt
cessation of enoxaparin therapy once a therapeutic INR is achieved. Conclusions
regarding the utility of outpatient bridging with fondaparinux or within the
HeartMate 3 population are unable to be made due to minimal inclusion during this
retrospective review.
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